Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.10) by 20 percent. This is a 78.95 percent increase over losses of $(0.38) per share from the same period last year. The company reported quarterly sales of $3.44 million which beat the analyst consensus estimate of $2.51 million by 36.94 percent. This is a 10.12 percent decrease over sales of $3.83 million the same period last year.